Explore this overview of the FDA’s newly finalized guidance, “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions,” and its impact on in vitro diagnostic (IVD) device manufacturers.
This Expert Insights whitepaper by Chenghui Yu, Senior Optical Engineer at DCN Dx, sheds light on the FDA’s newly heightened cybersecurity requirements for software-enabled IVD devices. It also emphasizes the significance of comprehensive cybersecurity measures for patient safety and corporate responsibility.
Key Insights You’ll Discover:
- Expanded Scope of Applicability: Understanding the FDA’s broader compliance requirements for devices with any programmable logic.
- Lifecycle Risk Management: The importance of continuous cybersecurity vigilance and adaptation throughout a device’s lifecycle.
- Secure Product Development Framework (SPDF): Strategies for integrating cybersecurity at every stage of device development.
- Impact on Small IVD Device Developers: Challenges and solutions for smaller manufacturers, exemplified by DCN Dx’s miniDxR device.
- And more!
This whitepaper provides an overview of the FDA’s new cybersecurity guidelines. It is a vital resource for IVD manufacturers and stakeholders in understanding and navigating the complexities of medical device cybersecurity. However, as the cybersecurity landscape is constantly evolving, it is important to review the FDA website for up-to-date information.
Download now for our insights into the new standard of IVD device cybersecurity!
